Ed Yaworski has served as Chief Technology Officer of Genevant Sciences Corporation since November 2021. Previously, he was VP, Pharmaceutical Development. Prior to joining Genevant at its inception in April 2018, Ed directed and led CMC activities at Arbutus Biopharma. He brings nearly 30 years of experience in the pharmaceutical industry, including 18 years working with nucleic acid delivery systems. Ed is an inventor of leading lipid nanoparticle delivery technology used in more than a dozen clinical trials. Ed holds an MSc. In Chemistry from the University of Manitoba.